Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter ...
Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth ...
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward ...
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per ...
A group of experts explore the advantages of purpose-built artificial intelligence (AI) for healthcare over generic models.
FDA grants accelerated approval to INOVIO’s Voceryq for reducing surgery frequency in adults with recurrent respiratory ...
Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. argenx signed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results